Cadila Pharmaceuticals

Last updated

Cadila Pharmaceuticals Limited
Company type Private
Industry Pharmaceuticals
Founded1951
Founder Indravadan Modi
Headquarters
Ahmedabad, Gujarat
,
India
Key people
Rajiv Modi
(Chairman and Managing Director)
Products APIs, generic drugs
Services
RevenueIncrease2.svg₹3,675 crore (US$440 million) (FY23) [1]
Decrease2.svg₹−10 crore (US$−1.2 million) (FY23) [1]
Number of employees
8,000
Subsidiaries IRM Ltd
Website www.cadilapharma.com

Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates, finished formulations, food supplements, biotechnology products and pharmaceutical machinery. [2]

Contents

History

In 1951 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friend Ramanbhai Patel. The company started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation. [3]

The Modi and Patel families decided to split the business in 1995, and two entities were formed: Cadila Pharmaceuticals Ltd (owned and controlled by Indravadan Modi and his son Rajiv Modi) and Cadila Healthcare (owned by Ramanbhai Patel and his son Pankaj Patel family). [3]

In 2014, a cautionary notice appeared on the US Food and Drug Administration (FDA) website, highlighting substantial manufacturing practice discrepancies discovered by inspectors in March at Cadila Pharmaceuticals' Ankleshwar facility in Gujarat. [4] This incident marked one among several Indian pharmaceutical companies receiving regulatory warnings from the FDA, indicating increased scrutiny on generic drugmakers. [5] A similar kind of notices were again issued in 2016 [6] and 2019. [7]

In 2018, the chairman of the company, Rajiv Modi, went through a widely publicized and contentious divorce with his wife, Monica, who comes from a prominent Mumbai-based business family of Garware. At that time, Modi transferred ₹200 crore (US$24 million) to Monica, who relinquished her rights, while custody of their son was awarded to Modi. [8] [9]

In 2019, Cadila Pharmaceuticals formed a partnership with Norwegian start-up, Serca Pharmaceuticals to develop new treatment for heart patients. [10]

In December 2023, Gujarat Police complied with a Gujarat High Court order, initiating a case against Rajiv Modi. [11] The case involves accusations of rape, assault, and intentional insult by a Bulgarian woman employed as a flight attendant and personal assistant at the company. She reported multiple instances of sexual harassment from February to March 2023, stating that she was terminated in April 2023 after resisting Modi's alleged “illicit demands”. [12] [13]

In November 2023, the company opened an active pharmaceutical ingredient (API) plant in Dahej, in Gujarat's Bharuch district. The facility was built with an investment of ₹200 crore, and is equipped with distributed control system (DCS) automation technology. [14]

Operations

Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia) and 2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility. [15]

Research

Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 105,000 sq. ft. area at Dholka, Gujarat, India which is staffed by 300 scientists.[ citation needed ]

The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs. [16]

Products and services

The Samba plant specializes in the production of a wide variety of drugs, totaling 140 types. It was commissioned in September 2002, showcasing Cadila Pharmaceuticals' commitment to expanding its manufacturing capabilities. With an expansive area of 11 acres, the plant represents a significant investment in pharmaceutical manufacturing infrastructure in the region. The project type being derivative indicates a focus on producing pharmaceutical derivatives or derivative-based products. The total budget for the project is 100 crores.The project was expected to be complete within around 800 days from the date of commencement. Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – 'Rabeloc'. [17] In 2009, the world's first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – 'Risorine' [18] and world's first drug combination for prevention of Cardiovascular Diseases – 'Polycap' were introduced by Cadila Pharmaceuticals. [19] For the patients with Non Small Cell Lung Cancer (NSCLC), the company introduced 'Mycidac-C' - first in the class active immunotherapy as well as drug targeting Desmocollin. [20] Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D, Mycobutol and Sepsivac.[ citation needed ]

On 4 March 2024, Cadila Pharmaceuticals announced the launch of Cadiflu Tetra, a quadrivalent influenza vaccine approved for use in adults and children by the Drugs Controller General of India (DCGI), using proprietary technology with nano-sized particles to mimic the virus's external structure without containing its genetic material. [21]

Related Research Articles

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

Ramanbhai B. Patel was an Indian chemist who founded the operation, along with school friend I A Modi, that eventually became the Ahmedabad-based pharmaceutical company Cadila Laboratories.

Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

<span class="mw-page-title-main">Zydus Lifesciences</span> Indian multinational pharmaceutical company

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacturing of generic drugs. The company ranked 100th in the Fortune India 500 list in 2020.

<span class="mw-page-title-main">Vibrant Gujarat</span> Biennial investors summit in Gujarat, India

Vibrant Gujarat, also referred to as Vibrant Gujarat Global Summit, is a biennial investors' global business event that is held in the state of Gujarat, India. The event is aimed at bringing together business leaders, investors, corporations, thought leaders, policy and opinion makers; the summit is advertised as a platform to understand and explore business opportunities in Gujarat. The summit's primary objective is to promote Gujarat as an attractive investment destination and to facilitate partnerships and collaborations across different sectors. Summit began in 2003 and is now held every two years.

<span class="mw-page-title-main">Economy of Gujarat</span>

The economy of Gujarat, a state in Western India, is the most industrialised in India, having the highest industrial output of any state in the union. It has the highest exports of any Indian state, accounting for 33% of all Indian exports in 2022–23. It leads in diverse industrial sectors such as chemicals, petrochemicals, dairy, drugs and pharmaceuticals, cement and ceramics, gems and jewellery, textiles and engineering. It has the highest Electricity Production Capacity and Maritime Port Cargo Volume among all states in India. It also has significant agricultural production with major agricultural produce of the state being cotton, groundnuts (peanuts), dates, sugar cane, milk and milk products. Gujarat recorded the lowest unemployment rate in India in 2022, with 4.4% of the labour force being unemployed.

Pankaj Ramanbhai Patel is an Indian billionaire businessman, and the chairman of Zydus Lifesciences, the fifth largest pharmaceutical company in India.

<span class="mw-page-title-main">Ahmedabad Metro</span> Rapid transit system in Ahmedabad and Gandhinagar, Gujarat, India

Ahmedabad Metro is a rapid transit system for the cities of Ahmedabad and Gandhinagar in Gujarat state of India. Currently the System is 58.66 km (36.450 mi) and has 38 stations.

Hansanagari also known as Hansot, is a village in Bharuch district, Southern Gujarat, India. It is about 15.0 km (9.3 mi) southwest of the city of Bharuch, and south of the Narmada River. The village and its surrounding taluka were acquired by the British in 1775, and subsequently returned to the local princely rulers in 1783, being finally incorporated into the Broach district of the Bombay Presidency in 1803.

Indravadan Ambalal Modi was an Indian pharmaceuticals industrialist who founded Cadila Pharmaceuticals in Ahmedabad. He is popularly known as the 'Medicine Man of India' for his contribution to the pharmaceutical industry of India post independence.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Glenmark Pharmaceuticals</span> Indian multinational pharmaceutical company

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India.

Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules and injectables. The company produces gynaecology, cardiovascular, oncology and blood therapeutic drugs, HIV antivirals and other anti-infectives, and vitamins and minerals.

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India. Its market presence is in more than 100+ countries.

<span class="mw-page-title-main">Amneal Pharmaceuticals</span> American publicly traded generics and specialty pharmaceutical company

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara. It is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates. It is also termed to be a market leader in macrolides segment of anti-infective drugs in India.

<span class="mw-page-title-main">Ketan R. Patel</span> Indian entrepreneur, scientist and pharmacist

Dr. Ketan R. Patel is an Indian pharmacist, Innovator, and serves as the Chairman & Managing Director of Troikaa Pharmaceuticals Ltd., a pharmaceutical company headquartered in Gujarat, India.

The Pharmaceutical industry in Gujarat ranks number one in India with a 33% share in drug manufacturing and a 28% share in drug exports. The state has 130 USFDA certified drug manufacturing facilities. Ahmedabad and Vadodara are considered as pharmaceutical hubs as there are many big and small pharma companies established in these cities.

Troikaa Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Ahmedabad city of Gujarat, India. It is a public unlisted company and is classified as company limited by shares.

Lincoln Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat, India. Lincoln Pharmaceuticals is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products.

References

  1. 1 2 "Cadila Pharmaceuticals Limited" . Crediwatch. Retrieved 18 December 2023.
  2. ↑ Bureau, BL Ahmedabad (22 March 2023). "Cadila Pharma to expand and upgrade its existing facilities in Gujarat". BusinessLine. Retrieved 11 September 2023.{{cite web}}: |last= has generic name (help)
  3. 1 2 Das, Sohini (28 January 2014). "Carrying the legacy forward: Rajiv Modi" – via Business Standard.
  4. ↑ Mishra, Digbijay; Das, Sohini (13 November 2014). "US FDA scolds Cadila Pharma over manufacturing practice in Gujrat plant" . Retrieved 6 January 2024.
  5. ↑ "FDA warns Cadila Pharma over drug production processes". Reuters . 12 November 2014. Retrieved 6 January 2023.
  6. ↑ RAJAGOPAL, DIVYA (1 January 2016). "Cadila gets US FDA warning for violating standards at Moraiya and Ahmedabad plants". The Economic Times. ISSN   0013-0389 . Retrieved 6 January 2024.
  7. ↑ Research, Center for Drug Evaluation and (28 November 2022). "Cadila Healthcare Limited - 584856 - 10/29/2019". Center for Drug Evaluation and Research. Retrieved 6 January 2024.
  8. ↑ "Gujarat: Cadila Pharma owner pays wife Rs 200 crore". The Times of India. 31 October 2018. ISSN   0971-8257 . Retrieved 6 January 2024.
  9. ↑ "Cadila Pharmaceuticals boss Rajiv Modi swallows a Rs 200-cr divorce pill". DNA India. Retrieved 6 January 2024.
  10. ↑ "Cadila Pharma inks pact with Norwegian start-up to develop new treatment for heart patients". @businessline. 10 January 2019. Retrieved 11 January 2019.
  11. ↑ Khatri, Dhananjay (24 December 2023). "Gujarat HC orders probe against Cadila Pharma CMD into rape allegations". CNBCTV18. Retrieved 6 January 2024.
  12. ↑ "Cops register FIR against Cadila CMD for rape of Bulgarian woman after Gujarat HC order". The Indian Express. 31 December 2023. Retrieved 6 January 2024.
  13. ↑ PTI. "Gujarat police register rape case against Cadila Pharma CMD after HC order". Deccan Herald. Retrieved 6 January 2024.
  14. ↑ "Business today".
  15. ↑ Financial Express 28 January 2013
  16. ↑ "Welcome to India in Business". www.indiainbusiness.nic.in. Archived from the original on 7 July 2014. Retrieved 24 March 2014.
  17. ↑ Bureau, Our Regional (16 July 2004). "Cadila Pharma unveils acidity drug in IV form" – via Business Standard.{{cite web}}: |last= has generic name (help)
  18. ↑ "Cadila launches new drug for TB treatment". dna. 31 October 2009.
  19. ↑ "Cadila Pharmaceuticals launches Polycap, which reduces cardiovascular and stroke risk substantially". The Financial Express. 2 April 2009.
  20. ↑ "Economic Times 21 November 2013". Archived from the original on 18 February 2014.
  21. ↑ Bureau, BL Ahmedabad (4 March 2024). "Cadila Pharmaceuticals launches advanced Quadrivalent Influenza Vaccine". BusinessLine. Retrieved 4 March 2024.{{cite web}}: |last= has generic name (help)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.